Sixin Glass Secures Over RMB 300 Million in New Funding to Advance Strategic Position in High-End Pharmaceutical Packaging Materials, Win-Win Capital Serves as Exclusive Financial Advisor Again

VCBeat has learned that recently,CANGZHOU FOUR STARS GLASS CO.,LTD (hereinafter referred to as “FOUR STARS”), a leading domestic enterprise in pharmaceutical neutral borosilicate glass Announced Another Over-RMB 300 million in financing, with cumulative financing exceeding RMB 500 million in the short term. This round of financing was led by GTJALead investment, with follow-on investments from Guangxi Xinggui Fund, Nanning High-Tech Fund, and Guangxi Shenhong Zhongheng Fund under Shenwan Hongyuan Securities.Kaicheng CapitalContinueServe as Exclusive Financial Advisor。The financing will be used to advance the construction of Guangxi Nanning Four Stars Pharmaceutical’s intelligent manufacturing base for its entire industrial chain, marking a strategic advancement by FOUR STARS in the field of high-end pharmaceutical packaging materials and accelerating the formation of a full-chain development pattern that integrates upstream key materials with downstream application scenarios.

FOUR STARS is a leading technology-driven enterprise in the field of new materials for high-end pharmaceutical packaging. The company has obtained over 90 national patents, including more than 40 invention patents, and possesses two key core technologies that fill gaps in the domestic industry. First, its "cold-top all-electric melting Vello process" for producing neutral borosilicate glass tubes is a world-first and the only green, environmentally friendly, energy-efficient, zero-emission innovative technology internationally, leading the global industry by 20 years. Second, its "full domestication of the pre-filled syringe industrial chain" technology has broken the long-standing monopoly held by developed countries in Europe and America, achieving comprehensive domestic production of pre-filled syringes—from raw materials to manufacturing equipment and technical processes—thereby realizing import substitution.Leveraging these two key core technologies, FOUR STARS has transformed its competitive advantage from a single product into a competitive advantage across the entire industrial chain. The company has put into operation China’s first “Intelligent Manufacturing Base for the Domestication of the Pharmaceutical Industrial Chain.” This base adopts a CMPO super-factory model that integrates “glass tubes + glass bottles and pre-filled syringes + contracted drug production,” featuring intensive, intelligent manufacturing across the full industrial chain. It serves not only as a cost control center but also as an innovative model that drives industrial upgrading, balances stakeholder interests, and promotes high-quality, sustainable industry development. This model will reshape China’s pharmaceutical industry, ushering it into a new stage characterized by a more professional and collaborative industrial ecosystem.

This financing round marks the capital market’s recognition of breakthroughs in underlying technologies and commercialization capabilities in pharmaceutical glass and pre-filled syringes, and will accelerate the implementation of FOUR STARS’ new technologies, new models, and new business formats, as well as its industrial expansion.

Wang Huanyi, Chairman of FOUR STARSStatement: Neutral borosilicate glass is an indispensable key foundational material in the biopharmaceutical industry chain. Over the past 20 years, FOUR STARS has remained committed to its mission, continuously investing in R&D and innovation centered on new technologies, new products, and new business models, thereby safeguarding national medication safety and ensuring the autonomy and controllability of the industry chain. Looking ahead, the company will continue to regard innovation as its fundamental driving force, focus on intelligent manufacturing as its primary direction, and leverage green energy as its strategic support. During the 15th Five-Year Plan period, it will strive to promote high-quality and sustainable development within the industry.

Teng Yuhang, Executive Partner at GTJA InvestmentFOUR STARS has long been deeply engaged in the field of pharmaceutical packaging materials. Through independent innovation, it has successfully overcome and mastered critical bottleneck technologies in key core processes, such as the drawing of neutral borosilicate glass tubes and bottle manufacturing, achieving large-scale commercialization both domestically and internationally and securing a leading market position. Following this financing round, we will collaborate with partners to provide continuous post-investment support for FOUR STARS’ subsequent capacity expansion and market development. As policies and the market continue to drive growing demand for high-end pharmaceutical glass products, we look forward to FOUR STARS leveraging its unique characteristics and advantages to further promote the development of China’s pharmaceutical glass industry.

Lin Xiaomei, Executive Director and General Manager of Nanning High-Tech CapitalIt was stated that FOUR STARS is a key investment attraction project for the High-Tech Zone in 2025 and a typical case of our “capital-based investment attraction” strategy. The High-Tech Zone is currently prioritizing the development of the food, drug, and health industries, and has established the Nanning Branch of the Guangxi Zhuang Autonomous Region Food and Drug Evaluation and Inspection Center to further optimize enterprise services and improve approval and registration efficiency. As a leading enterprise in the pharmaceutical glass industry, the establishment of FOUR STARS in the Nanning High-Tech Zone is expected to drive the agglomeration of upstream and downstream pharmaceutical industry chains within the park, thereby assisting the High-Tech Zone in building a distinctive and complete food, drug, and health industrial chain.

Qin Li, Director at Kaicheng Capital and Co-Head of the KA TeamFOUR STARS has established formidable barriers in the high-end pharmaceutical packaging sector through breakthroughs in core technologies and a comprehensive industrial chain layout. Against the backdrop of continuous upgrades in the pharmaceutical industry and the accelerated substitution of imported products with domestically produced alternatives, the company is poised to further unleash its production capacity and technological advantages. Kaicheng Capital is honored to continue serving as the exclusive financial advisor for this financing round and looks forward to FOUR STARS’ continued leadership in driving the high-quality development of China’s pharmaceutical glass industry.